Wearable smartwatch monitoring arrhythmias for patients who at high risk of pacemaker implantation after transcatheter aortic valve replacement

Ailifeire Aihemaiti,Jiaqi Fan,Abuduwufuer Yidilisi,Xianbao Liu,Jian'an Wang

DOI: https://doi.org/10.1093/ehjdh/ztad060

2023-01-01

Abstract:Graphical Abstract

What problem does this paper attempt to address?

Wearable Smartwatch Facilitated Remote Health Management for Patients Undergoing Transcatheter Aortic Valve Replacement

Xianbao Liu,Jiaqi Fan,Yuchao Guo,Hanyi Dai,Jianguo Xu,Lihan Wang,Po Hu,Xinping Lin,Cheng Li,Dao Zhou,Huajun Li,Jian'an Wang

DOI: https://doi.org/10.1161/jaha.121.023219

2022-01-01

Abstract:Background In the recent decades, the development of novel digital health technologies enables doctors to monitor ECG and vital signs remotely. But the data on applying the noninvasive wearable smartwatch on patients with transcatheter aortic valve replacement (TAVR) are unknown. Methods and Results We performed a prospective, observational cohort study to evaluate the feasibility of a novel, virtual, and remote health care strategy for patients with TAVR discharged to home with smart wearable devices. A total of 100 consecutive patients with severe aortic stenosis who underwent elective transfemoral TAVR were enrolled and received the Huawei smartwatch at least 1 day before TAVR. Vital signs, including heart rate, rhythm, oxygen saturation, and activity, were continuously recorded. Single‐lead ECG was recorded twice per day in the week following TAVR discharge and at least 2 days a week for the subsequent month after TAVR discharge. A designated heart team member provided remote health care with the data from the smartwatch when the patient had a need. Thirty‐eight cardiac events were reported in 34 patients after discharge, with most of the events (76.0%) detected and confirmed by the smartwatch. Six patients were advised and readmitted to the hospital for arrhythmia events detected by the smartwatch, of whom 4 patients received pacemaker implantation. The remaining 28 (82.4%) patients received telemedicine monitoring instead of face‐to‐face clinical visits, and 3 of them received new medication treatment under the online guidance of doctors. New‐onset left branch bundle block was found in 48 patients, with transient characteristics, and recovered spontaneously in 30 patients, and new‐onset atrial fibrillation was detected in 4 patients. There were no significant differences in the average weekly heart rates or the ratio of abnormal or low oxygen saturation when compared with the baseline. The average daily steps increased over time significantly (baseline, 870±1353 steps; first week, 1986±2406 steps; second week, 2707±2716 steps; third week, 3059±3036 steps; fourth week, 3678±3485 steps, P <0.001). Conclusions Smartwatches can facilitate remote health care for patients discharged to home after undergoing TAVR and enable a novel remote follow‐up strategy. The majority of cardiac clinical events that occurred within 30‐day follow‐up were detected by the smartwatch, mainly because of the record of conduction abnormality. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04454177.
Smartwatch Facilitated Remote Health Care for Patients Undergoing Transcatheter Aortic Valve Replacement Amid COVID-19 Pandemic

Xianbao Liu,Jiaqi Fan,Yuchao Guo,Hanyi Dai,Jianguo Xu,Lihan Wang,Po Hu,Xinping Lin,Cheng Li,Dao Zhou,Huajun Li,Jian’an Wang

DOI: https://doi.org/10.1101/2021.05.22.21256870

2021-01-01

Abstract:ABSTRACTBACKGROUNDThe novel coronavirus disease-2019 (COVID-19 Pandemic) has brought difficulties to the management of patients undergoing transcatheter aortic valve replacement (TAVR).OBJECTIVESThis prospective, observational cohort study sought to evaluate the feasibility of a novel, virtual, and remote health care strategy for TAVR patients with smart wearable devices.METHODSA total of 100 consecutive severe aortic stenosis patients who underwent elective transfemoral TAVR were enrolled and each received a HUAWEI smartwatch at least one day before TAVR. Vital signs were continuously tracked and recorded. Single lead electrocardiogram (ECG) was recorded periodically after TAVR. A designated heart team member was to provide remote data-assisted health care to address the medical demand.RESULTSThirty-eight cardiac events were reported in 34 patients after discharge, with most of the events (76.0%) were detected and confirmed by the smartwatch. Six patients were advised and readmitted to the hospital for arrhythmia events, among whom, four received pacemaker implantations. The remaining 28 (82.4%) patients received telemedicine monitoring instead of face-to-face clinical visits, and three of them received new medication treatment under a doctor’s online guidance of doctors. New-onset LBBB was found in 48 patients with transient and recovered spontaneously in 30 patients, while new-onset atrial fibrillation in 4 patients. There were no significant differences in the average weekly heart rates, the ratio of abnormal or low oxygen saturation when compared with the baseline. The average daily steps increased over time significantly (baseline, 870±1353 steps; first week, 1986±2406 steps; second week, 2707±2716 steps; third week, 3059±3036 steps; fourth week, 3678±3485 steps, p < 0.001).CONCLUSIONSSmartwatch can facilitate remote health care for patients undergoing TAVR during COVID-19 and enables a novel remote follow-up strategy. The majority of cardiac clinical events that occurred within 30-day follow-up were detected by the smartwatch, mainly due to the record of conduction abnormality. (SMART Watch Facilitated Early Discharge in Patients undergoing Transcatheter Aortic Valve Replacement, NCT04454177).
Smartwatch-Detected Arrhythmias in Patients After Transcatheter Aortic Valve Replacement (TAVR): Analysis of the SMART TAVR Trial

Jiaqi Fan,Hanyi Dai,Yuchao Guo,Jianguo Xu,Lihan Wang,Jubo Jiang,Xinping Lin,Cheng Li,Dao Zhou,Huajun Li,Xianbao Liu,Jian'an Wang

DOI: https://doi.org/10.2196/41843

IF: 7.076

2024-07-20

Journal of Medical Internet Research

Abstract:Background: There are limited data available on the development of arrhythmias in patients at risk of high-degree atrioventricular block (HAVB) or complete heart block (CHB) following transcatheter aortic valve replacement (TAVR). Objective: This study aimed to explore the incidence and evolution of arrhythmias by monitoring patients at risk of HAVB or CHB after TAVR using smartwatches. Methods: We analyzed 188 consecutive patients in the prospective SMART TAVR (smartwatch-facilitated early discharge in patients undergoing TAVR) trial. Patients were divided into 2 groups according to the risk of HAVB or CHB. Patients were required to trigger a single-lead electrocardiogram (ECG) recording and send it to the Heart Health App via their smartphone. Physicians in the central ECG core lab would then analyze the ECG. The incidence and timing of arrhythmias and pacemaker implantation within a 30-day follow-up were compared. All arrhythmic events were adjudicated in a central ECG core lab. Results: The mean age of the patients was 73.1 (SD 7.3) years, of whom 105 (55.9%) were men. The mean discharge day after TAVR was 2.0 (SD 1.8) days. There were no statistically significant changes in the evolution of atrial fibrillation or atrial flutter, Mobitz I, Mobitz II, and third-degree atrial ventricular block over time in the first month after TAVR. The incidence of the left bundle branch block (LBBB) increased in the first week and decreased in the subsequent 3 weeks significantly ( P <.001). Patients at higher risk of HAVB or CHB received more pacemaker implantation after discharge (n=8, 9.6% vs n=2, 1.9%; P =.04). The incidence of LBBB was higher in the group with higher HAVB or CHB risk (n=47, 56.6% vs n=34, 32.4%; P =.001). The independent predictors for pacemaker implantation were age, baseline atrial fibrillation, baseline right bundle branch block, Mobitz II, and third-degree atrioventricular block detected by the smartwatch. Conclusions: Except for LBBB, no change in arrhythmias was observed over time in the first month after TAVR. A higher incidence of pacemaker implantation after discharge was observed in patients at risk of HAVB or CHB. However, Mobitz II and third-degree atrioventricular block detected by the smartwatch during follow-ups were more valuable indicators to predict pacemaker implantation after discharge from the index TAVR. Trial Registration: ClinicalTrials.gov NCT04454177; https://clinicaltrials.gov/study/NCT04454177

health care sciences & services,medical informatics
Ambulatory Smartwatch ECG Monitoring among Patients Undergoing Transcatheter Aortic Valve Replacement Early after Discharge: an Observational Study

Yi Zhang,Tian -Yuan Xiong,Xue-Mei Yang,De -Fang Chen,Yi-Ming Li,Yun Bao,Mao Chen

DOI: https://doi.org/10.31083/j.rcm2401011

2023-01-01

Reviews in Cardiovascular Medicine

Abstract:Background: As an emerging arrhythmia monitor, ambulatory smartwatch electrocardiogram (ECG) provides an option for home-based monitoring of delayed new-onset arrhythmic events after transcatheter aortic valve replacement (TAVR). We aimed to validate the diagnostic efficacy of a consumer smartwatch ECG in TAVR recipients, while further explore the occurrence rate of both tachy- and brady-arrhythmia for 30 days after discharge to support risk management. Methods: Consecutive TAVR recipients from February 26th, 2021 to December 13th, 2021 were enrolled prospectively, receiving simultaneous 24-hour Holter and 12-lead ECG compared with smartwatch ECG during hospitalization and daily smartwatch ECG collection for 30 days after discharge. Results: Among 110 patients, the efficacy of smartwatch ECG presented sensitivity and specificity in diagnosing atrial fibrillation (AF) as 1.00 and 0.97, left bundle branch block (LBBB) as 0.61 and 0.88, and right bundle branch block (RBBB) as 0.60 and 0.97, respectively, compared with 24-hour Holter; presented sensitivity and specificity in diagnosing AF as 0.88 and 1.00, LBBB as 0.90 and 0.96, and RBBB as 0.83 and 0.94, respectively, compared with 12-lead ECG. At 30-day follow-up, new-onset arrhythmia included new-onset severe conduction disturbance (SCD) (23.6%), new-onset AF (21.8%), new-onset permanent LBBB (14.5%) and new-onset permanent RBBB (0.9%); 69.2% (36/52) of early new-onset LBBB recovered at 30-day follow-up. Conclusions: The diagnostic efficacy of consumer smartwatch ECG in arrhythmic events among TAVR population was acceptable, which provided a recommendable option for home-based management. Clinical Trial Registration: “Continuously ambulatory rhythm monitoring and predictors of electrocardio-related adverse events in 30 days after transcatheter aortic valve replacement”; Identifier: ChiCTR2000041244; http://www.chictr.org.cn/showproj.aspx?proj=66324.
Abstract 12465: Clinical Results of a Novel Chest-Based Wearable During Transcatheter Aortic Valve Replacement Surgery for Real-Time Remote Monitoring

Alexi Charalambides,Rohith Krishnan Pillai,Maahin Beri,Jesse Carpenter,Brian Stancil,Carmel Majidi,Philip Leduc,Louis Rauso,Dustin Kliner,Derek Serna-Gallegos,Catalin Toma,Saurabh Sanon,Ibrahim Sultan,Alexi CharalambidesRohith Krishnan PillaiMaahin BeriJesse CarpenterBrian StancilCarmel MajidiPhilip LeducLouis RausoDustin KlinerDerek Serna-GallegosCatalin TomaSaurabh SanonIbrahim SultanLifeware Labs,Pittsburgh,PAMechanical Engineering,Carnegie Mellon Univ,Pittsburgh,PADept of Anesthesiology and Perioperative Medicine,UPMC,Pittsburgh,PAUniv of Pittsburgh Med Cntr,Pittsburgh,PAUniv of Pittsburgh Med Ce,Pittsburgh,PAUniv of Pittsburgh,Pittsburgh,PA

DOI: https://doi.org/10.1161/circ.144.suppl_1.12465

IF: 37.8

2021-11-10

Circulation

Abstract:Circulation, Volume 144, Issue Suppl_1, Page A12465-A12465, November 16, 2021. Objective:Transcatheter Aortic Valve Replacement (TAVR) is the most common strategy for treating stenotic aortic valves in older adults. However, up to 18% of patients in the US are readmitted within 30 days, with about a third of these patients readmitted due to cardiac issues [1]. It would therefore be desirable to monitor discharged patients remotely to catch early signs of deterioration before more serious complications occur, and thereby reduce hospital readmission rates. The current gold standard for arrhythmia monitoring involves a single-lead Holter monitor in the form of a wearable chest-based patch. However, these devices usually do not track cardiac rhythms in real-time, and are typically mailed in after the wear period is over resulting in further delays.Methods:A novel chest patch capable of single-lead ECG that achieves real-time monitoring via Bluetooth and smartphone communications was used. To validate, the patch was placed on the chest of patients undergoing a TAVR; ECG was recorded and compared to gold-standard equipment.Results:ECG rhythms were collected from four patients using the patch and compared to an institutional hemodynamic monitoring system (GE MACLAB). The ECGs from each system were time aligned using a Fourier Transform method [2], R-peaks were identified using the Pan-Tompkins algorithm, heart rates were calculated over the course of the procedure by averaging R-R intervals over a 10 sec sliding window, and lastly Pearson correlation coefficients were calculated between the patch and gold-standard equipment. Pearson coefficients ranged from 0.995 to 0.999 with a Mean Absolute Error of 0.55 BPM and Root Mean Square Error of 2 BPM (see fig).Conclusion:These early results suggest an excellent agreement and accuracy between the wearable device and gold-standard ECG equipment, and may pave the way for monitoring discharged patients remotely. [1] Kolte, Dhaval et al 2017 [2] Fridman, Lex et al 2016

cardiac & cardiovascular systems,peripheral vascular disease
Daily Physical Activity Measured by Wearable Smartwatch for Patients Undergoing Transcatheter Aortic Valve Replacement: Insights from the SMART TAVR Study.

Jiaqi Fan,Qiong Liu,Hanyi Dai,Dao Zhou,Yuchao Guo,Jianguo Xu,Lihan Wang,Po Hu,Jubo Jiang,Xinping Lin,Cheng Li,Xianbao Liu,Jian'an Wang

DOI: https://doi.org/10.1161/circoutcomes.123.010066

2024-01-01

Abstract:BACKGROUND: This study aims to evaluate limited data about daily physical activity patterns, influential factors, and their association with 1-year mortality or rehospitalization after transcatheter aortic valve replacement (TAVR) through smartwatches. METHODS: Consecutive severe aortic stenosis patients undergoing elective transfemoral TAVR in a Chinese tertiary hospital were enrolled from July 2021 to May 2022 and received a Huawei smartwatch at least 1 day before TAVR. The primary outcome was a composite of all-cause mortality or hospital readmission within 1 year. Linear mixed-effects models were applied to determine influential factors of daily step counts, and Cox proportional hazard regression models were to estimate the association between baseline step counts within 1 month since discharge and composite outcome from months 2 to 12. The dose-response association was assessed using restricted cubic spline curves. RESULTS: A total of 222 participants and 59 469 valid monitoring person-day records were included (mean age, 72.7 years; 61% women). Step counts increased rapidly within the first 2 months ( P <0.001), followed by a slower increase for those without composite outcomes ( P =0.029) and a gradual decrease for those who developed composite outcomes ( P <0.001). In multivariate linear mixed models, a 1-m increase in baseline 6-minute walk test and a 1-month delay after discharge were associated with 4 (95% CI, 1–7) and 170 (95% CI, 145–194) additional step counts, respectively. In restricted cubic spline analysis, the hazard ratio declined progressively until ≈5000 steps per day, after which they leveled. Below 5000 steps, the adjusted hazard ratio of composite outcome associated with each 1000-step count increase was 0.67 (0.50–0.89; P =0.007). However, above 5000 steps, step counts were not significantly associated with the composite outcome ( P =0.645), with a hazard ratio of 1.12 (0.70–1.79). CONCLUSIONS: Daily step counts rapidly increased within the first 2 months post-TAVR. Increased physical activity was associated with a lower risk of 1-year mortality or rehospitalization after TAVR for patients with daily step counts below 5000. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04454177.
Watch for tachycardia

Oliver Galgut,Pierre Le Page,Andrew R. J. Mitchell

DOI: https://doi.org/10.1186/s42444-022-00081-z

2022-11-14

International Journal of Arrhythmia

Abstract:Abstract Background Wearable devices capable of measuring health metrics are becoming increasingly prevalent. Most work has investigated the potential for these devices in the context of atrial fibrillation, our case highlights the potential of wearable devices across a wider range of arrhythmia. Case presentation A 51-year-old woman was referred to the cardiology clinic for an assessment of symptoms of intermittent exertional shortness of breath and palpitation. The patient was otherwise fit and well, took limited alcohol and no caffeine, and was a never smoker. There was no family history of heart disease. Physical examination in clinic was unremarkable, and a 12-lead electrocardiogram (ECG), seven-day ambulatory ECG, exercise stress ECG, and trans-thoracic echocardiogram were all normal. During a severe episode the patient recorded an ECG using an Apple Watch (Apple Inc, California, USA). This was forwarded to the patient’s cardiologist, who suspected a broad complex tachycardia and organised an urgent follow-up appointment. A further 72-h Holter ECG monitor showed frequent sustained periods of monomorphic ventricular tachycardia, confirming the watch findings. The patient was started on beta blocker therapy with a rapid improvement in symptoms. Conclusions Current smartwatch technology can reliably identify irregular rhythms and can distinguish atrial fibrillation from sinus rhythm, with emerging evidence supporting detection of other cardiovascular diseases, including medical emergencies. There may also be a role for wearable devices in screening young populations for predictors of sudden cardiac death. At present device outputs require clinician interpretation, but in the future patients may present to primary or secondary care with a firm diagnosis of arrhythmia and may already be making wearable device guided behaviour changes.
The value of smart watch in diagnosis of atrial fibrillation and left bundle branch block after transcatheter aortic valve replacement

党梦秋,范嘉祺,戴晗怡,陈俊,李然犀,徐建国,李程,郭宇超,刘先宝,王建安

DOI: https://doi.org/10.3877/cma.j.issn.2095-6568.2023.01.005

2023-01-01

Abstract:Objective:To explore the value of smart watch in diagnosis of atrial fibrillation (AF) and left bundle branch block (LBBB) after transcatheter aortic valve replacement (TAVR).Methods:The patients who underwent trans-femoral TAVR in the Department of Cardiology, The Second Affiliated Hospital Zhejiang University School Of Medicine from July 2020 to March 2021 were included in this study. Electrocardiograms and single-lead electrocardiograms which were recorded by smart watch were analyzed before and after procedure. Receiver operating characteristic (ROC) curve was used to analysis the sensitivity and specificity of a smart watch in the diagnosis of AF and LBBB after TAVR.Results:A total of 202 patients were enrolled, including 117 male patients with an average age of (73.52±7.69) years. The sensitivity for diagnosing AF and LBBB was 88% and 84% respectively. In a total of 380 electrocardiograms recorded by smart watch, 4 false positives and 6 false negatives were happened in diagnosis of AF, while 10 false positives and 7 false negatives in identifing left bundle branch block.Conclusion:The sensitivity and specificity of smart watch in diagnosis of AF and LBBB in patients after TAVR are high. It can be considered identifying AF and LBBB after TAVR with smart watch.
Myocardial Infarction Detected by a Smartwatch after Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic

Xian-bao Liu,Jia-qi Fan,Ye-ming Xu,Yu-chao Guo,Cheng Li,Jian-guo Xu,Jian-an Wang

DOI: https://doi.org/10.5847/wjem.j.1920-8642.2021.03.018

2021-01-01

World Journal of Emergency Medicine

Abstract:Xian-bao Liu, Jia-qi Fan, Ye-ming Xu, Yu-chao Guo, Cheng Li , Jian-guo Xu, Jian-an Wang 1 Department of Cardiology, the Second Affi liated Hospital Zhejiang University School of Medicine, Hangzhou 310009, China 2 Zhejiang University School of Medicine, Hangzhou 310058, China 3 Department of Electrocardiography, the Second Affi liated Hospital Zhejiang University School of Medicine, Hangzhou 310009, China
Smart Wearables for Cardiac Monitoring-Real-World Use beyond Atrial Fibrillation

David Duncker,Wern Yew Ding,Susan Etheridge,Peter A Noseworthy,Christian Veltmann,Xiaoxi Yao,T Jared Bunch,Dhiraj Gupta

DOI: https://doi.org/10.3390/s21072539

2021-04-05

Abstract:The possibilities and implementation of wearable cardiac monitoring beyond atrial fibrillation are increasing continuously. This review focuses on the real-world use and evolution of these devices for other arrhythmias, cardiovascular diseases and some of their risk factors beyond atrial fibrillation. The management of nonatrial fibrillation arrhythmias represents a broad field of wearable technologies in cardiology using Holter, event recorder, electrocardiogram (ECG) patches, wristbands and textiles. Implementation in other patient cohorts, such as ST-elevation myocardial infarction (STEMI), heart failure or sleep apnea, is feasible and expanding. In addition to appropriate accuracy, clinical studies must address the validation of clinical pathways including the appropriate device and clinical decisions resulting from the surrogate assessed.
Remote monitoring of atrial fibrillation recurrence using mHealth technology (REMOTE-AF)

Gamith Adasuriya,Andrey Barsky,Ines Kralj-Hans,Siddhartha Mohan,Simrat Gill,Zhong Chen,Julian Jarman,David Jones,Haseeb Valli,Georgios V Gkoutos,Vias Markides,Wajid Hussain,Tom Wong,Dipak Kotecha,Shouvik Haldar

DOI: https://doi.org/10.1093/ehjdh/ztae011

2024-02-12

Abstract:Aims: This proof-of-concept study sought to evaluate changes in heart rate (HR) obtained from a consumer wearable device and compare against implantable loop recorder (ILR)-detected recurrence of atrial fibrillation (AF) and atrial tachycardia (AT) after AF ablation. Methods and results: REMOTE-AF (NCT05037136) was a prospectively designed sub-study of the CASA-AF randomized controlled trial (NCT04280042). Participants without a permanent pacemaker had an ILR implanted at their index ablation procedure for longstanding persistent AF. Heart rate and step count were continuously monitored using photoplethysmography (PPG) from a commercially available wrist-worn wearable. Photoplethysmography-recorded HR data were pre-processed with noise filtration and episodes at 1-min interval over 30 min of HR elevations (Z-score = 2) were compared with corresponding ILR data. Thirty-five patients were enrolled, with mean age 70.3 ± 6.8 years and median follow-up 10 months (interquartile range 8-12 months). Implantable loop recorder analysis revealed 17 out of 35 patients (49%) had recurrence of AF/AT. Compared with ILR recurrence, wearable-derived elevations in HR ≥ 110 beats per minute had a sensitivity of 95.3%, specificity 54.1%, positive predictive value (PPV) 15.8%, negative predictive value (NPV) 99.2%, and overall accuracy 57.4%. With PPG-recorded HR elevation spikes (non-exercise related), the sensitivity was 87.5%, specificity 62.2%, PPV 39.2%, NPV 92.3%, and overall accuracy 64.0% in the entire patient cohort. In the AF/AT recurrence only group, sensitivity was 87.6%, specificity 68.3%, PPV 53.6%, NPV 93.0%, and overall accuracy 75.0%. Conclusion: Consumer wearable devices have the potential to contribute to arrhythmia detection after AF ablation. Study registration: ClinicalTrials.gov Identifier: NCT05037136 https://clinicaltrials.gov/ct2/show/NCT05037136.
Smartwatch Performance for the Detection and Quantification of Atrial Fibrillation

Jeremiah Wasserlauf,Cindy You,Ruchi Patel,Alexander Valys,David Albert,Rod Passman

DOI: https://doi.org/10.1161/CIRCEP.118.006834

Abstract:Background Atrial fibrillation (AF) burden and duration appear to be related to stroke risk. A wearable consumer electronic device could provide long-term assessment of these measures inexpensively and noninvasively. This study compares the accuracy of an AF-sensing watch (AFSW; Apple Watch with KardiaBand) with simultaneous recordings from an insertable cardiac monitor (ICM; Reveal LINQ). Methods SmartRhythm 2.0, a convolutional neural network, was trained on anonymized data of heart rate, activity level, and ECGs from 7500 AliveCor users. The network was validated on data collected in 24 patients with ICMs and a history of paroxysmal AF who simultaneously wore the AFSW with SmartRhythm 0.1 software. The primary outcome was sensitivity of the AFSW for AF episodes ≥1 hour. Secondary end points included sensitivity of the AFSW for detection of AF by subject and sensitivity for total AF duration across all subjects. Subjects with >50% false-positive AF episodes on ICM were excluded. Results We analyzed 31 348.9 hours (mean (SD), 11.3 (4.4) hours/day) of simultaneous AFSW and ICM recordings in 24 patients. The ICM detected 82 episodes of AF ≥1 hour while the AFSW was worn, with a total duration of 1127.1 hours. Of these, the SmartRhythm 2.0 neural network detected 80 episodes (episode sensitivity, 97.5%) with a total duration of 1101.1 hours (duration sensitivity, 97.7%). Three of the 18 subjects with AF ≥1 hour had AF only when the watch was not being worn (patient sensitivity, 83.3%; or 100% during time worn). Positive predictive value for AF episodes was 39.9%. Conclusions An AFSW is highly sensitive for detection of AF and assessment of AF duration in an ambulatory population when compared with an ICM. Such devices may represent an inexpensive, noninvasive approach to long-term AF surveillance and management.
Validation of diagnostic wearable ECG data from high-risk patients and integration into the atrial fibrillation catheter ablation pathway

N Ahluwalia,G Saengkrajang,E Maclean,H Abbass,A Hussain,C Butcher,R J Schilling

DOI: https://doi.org/10.1093/eurheartj/ehae666.3421

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Wearables like the Apple Watch (AW) offer non-invasive, long-term monitoring and patient-led, single-lead ECG recordings. Although validated for Atrial Fibrillation (AF) detection in the general population, the accuracy and clinical utility of the single-lead ECG recording feature for the diagnosis of AF has not been evaluated in patients at high risk of atrial arrhythmias.(1) An evaluation of the accuracy of the Wearable-derived labels is important to determine the feasibility of integrating AW-based remote monitoring into clinical pathways. Objective To evaluate the accuracy and data burden from AW-based, patient-led ECG monitoring in patients undergoing AF catheter ablation. Methods Patients referred for first-time AF catheter ablation to the Study Institution between January 2022 and March 2023 were invited to enrol in the AF Follow-up with Apple Watch (AFFU-AW) Trial. Patients randomised to the active arm of the study received 12 months of post-ablation follow-up using a loaned Apple Watch. Participants underwent an education session and were asked to perform daily ECGs; sending through any labelled as AF, inconclusive, or in the context of symptoms. The accuracy of the automated ECG labelling was determined against blinded, independent labelling by two experienced Electrophysiologists. Results 1093 remote transmissions were emailed in for evaluation from 52 patients to the Study team. This was a median of 6 [2, 17] per patient and a receiver burden of 2 [1, 4] ECGs per day. 475 were categorised by the AW as AF with a sensitivity of 0.71 and specificity of 0.96 compared to expert labelling. 342 (31%) were not categorised by the wearable, with an 'inconclusive' interpretation (161 [47%]) or 'high heart rate' (108 [32%]) as the most cited reasons. 178 (55%) of the uncategorised ECGs were subsequently overread as AF. Accompanying symptoms were reported with 324 (30%) ECGs, most commonly palpitations. Conclusion This is the first reported evaluation of the AF diagnostic feature based on AW ECG recordings as part of a remote patient rhythm surveillance pathway after catheter ablation. The high positive predictive value of 'Sinus Rhythm' and 'AF' labels and the high specificity of the 'AF' label are comparable to diagnostic algorithms in implantable loop recorders.(2) The source code to automate data curation and structured databasing of wearable ECGs has been made available for care providers to integrate the service into device monitoring workflows.(3)

cardiac & cardiovascular systems
The Use of Electrocardiogram Smartwatches in Patients with Cardiac Implantable Electrical Devices

Marc Strik,Sylvain Ploux,Joske van der Zande,Anouk Velraeds,Leslie Fontagne,Michel Haïssaguerre,Pierre Bordachar

DOI: https://doi.org/10.3390/s24020527

IF: 3.9

2024-01-16

Sensors

Abstract:Unlimited access to ECGs using an over-the-counter smartwatch constitutes a real revolution for our discipline, and the application is rapidly expanding to include patients with cardiac implantable electronic devices (CIEDs) such as pacemakers (PMs) and implantable cardioverter defibrillators (ICDs). CIEDs require periodic evaluation and adjustment by healthcare professionals. In addition, implanted patients often present with symptoms that may be related to their PMs or ICDs. An ECG smartwatch could reveal information about device functioning, confirm normal device function, or aid in the case of device troubleshooting. In this review, we delve into the available evidence surrounding smartwatches with ECG registration and their integration into the care of patients with implanted pacemakers and ICDs. We explore safety considerations and the benefits and limitations associated with these wearables, drawing on relevant studies and case series from our own experience. By analyzing the current landscape of this emerging technology, we aim to provide a comprehensive overview that facilitates informed decision-making for both healthcare professionals and patients.

engineering, electrical & electronic,chemistry, analytical,instruments & instrumentation
Smart watch applications in atrial fibrillation detection: Current state and future directions

Rahul Vyas,Shubhika Jain,Anuj Thakre,Sahith Reddy Thotamgari,Sameer Raina,Vijaywant Brar,Partho Sengupta,Pratik Agrawal

DOI: https://doi.org/10.1111/jce.16451

IF: 2.7

2024-10-04

Journal of Cardiovascular Electrophysiology

Abstract:Introduction Atrial fibrillation (Afib) is a prevalent chronic arrhythmia associated with severe complications, including stroke, heart failure, and increased mortality. This review explores the use of smartwatches for Afib detection, addressing the limitations of current monitoring methods and emphasizing the potential of wearable technology in revolutionizing healthcare. Results/Observation Current Afib detection methods, such as electrocardiography, have limitations in sensitivity and specificity. Smartwatches with advanced sensors offer continuous monitoring, improving the chances of detecting asymptomatic and paroxysmal Afib. The review meticulously examines major clinical trials studying Afib detection using smartwatches, including the landmark Apple Heart Study and ongoing trials such as the Heart Watch, Heartline, and Fitbit Heart Study. Detailed summaries of participant numbers, smartwatch devices used, and key findings are presented. It also comments on the cost‐effectiveness and scalability of smartwatch‐based screening, highlighting the potential to reduce healthcare costs and improve patient outcomes. Conclusion/Relevance The integration of wearable technology into healthcare can lead to earlier diagnosis, improved patient engagement, and enhanced cardiac health monitoring. Despite ethical considerations and disparities, the potential benefits outweigh the challenges. This review calls for increased awareness, collaboration with insurance companies, and ongoing research efforts to optimize smartwatch accuracy and encourage widespread adoption of Afib detection. With insights from major trials, this review serves as a comprehensive reference for healthcare professionals and policymakers, guiding future strategies in the early diagnosis and management of atrial fibrillation.

cardiac & cardiovascular systems
Cardiac Health Assessment Using a Wearable Device Before and After Transcatheter Aortic Valve Implantation: Prospective Study

Rob Eerdekens,Jo Zelis,Herman ter Horst,Caia Crooijmans,Marcel van 't Veer,Danielle Keulards,Marcus Kelm,Gareth Archer,Titus Kuehne,Guus Brueren,Inge Wijnbergen,Nils Johnson,Pim Tonino

DOI: https://doi.org/10.2196/53964

2024-06-03

JMIR mhealth and uhealth

Abstract:Abstract Background Due to aging of the population, the prevalence of aortic valve stenosis will increase drastically in upcoming years. Consequently, transcatheter aortic valve implantation (TAVI) procedures will also expand worldwide. Optimal selection of patients who benefit with improved symptoms and prognoses is key, since TAVI is not without its risks. Currently, we are not able to adequately predict functional outcomes after TAVI. Quality of life measurement tools and traditional functional assessment tests do not always agree and can depend on factors unrelated to heart disease. Activity tracking using wearable devices might provide a more comprehensive assessment. Objective This study aimed to identify objective parameters (eg, change in heart rate) associated with improvement after TAVI for severe aortic stenosis from a wearable device. Methods In total, 100 patients undergoing routine TAVI wore a Philips Health Watch device for 1 week before and after the procedure. Watch data were analyzed offline—before TAVI for 97 patients and after TAVI for 75 patients. Results Parameters such as the total number of steps and activity time did not change, in contrast to improvements in the 6-minute walking test (6MWT) and physical limitation domain of the transformed WHOQOL-BREF questionnaire. Conclusions These findings, in an older TAVI population, show that watch-based parameters, such as the number of steps, do not change after TAVI, unlike traditional 6MWT and QoL assessments. Basic wearable device parameters might be less appropriate for measuring treatment effects from TAVI.

health care sciences & services,medical informatics
Clinical assessment of a non-invasive wearable MEMS pressure sensor array for monitoring of arterial pulse waveform, heart rate and detection of atrial fibrillation

Matti Kaisti,Tuukka Panula,Joni Leppänen,Risto Punkkinen,Mojtaba Jafari Tadi,Tuija Vasankari,Samuli Jaakkola,Tuomas Kiviniemi,Juhani Airaksinen,Pekka Kostiainen,Ulf Meriheinä,Tero Koivisto,Mikko Pänkäälä

DOI: https://doi.org/10.1038/s41746-019-0117-x

IF: 15.2

2019-05-14

npj Digital Medicine

Abstract:There is an unmet clinical need for a low cost and easy to use wearable devices for continuous cardiovascular health monitoring. A flexible and wearable wristband, based on microelectromechanical sensor (MEMS) elements array was developed to support this need. The performance of the device in cardiovascular monitoring was investigated by (i) comparing the arterial pressure waveform recordings to the gold standard, invasive catheter recording (n = 18), (ii) analyzing the ability to detect irregularities of the rhythm (n = 7), and (iii) measuring the heartrate monitoring accuracy (n = 31). Arterial waveforms carry important physiological information and the comparison study revealed that the recordings made with the wearable device and with the gold standard device resulted in almost identical (r = 0.9–0.99) pulse waveforms. The device can measure the heart rhythm and possible irregularities in it. A clustering analysis demonstrates a perfect classification accuracy between atrial fibrillation (AF) and sinus rhythm. The heartrate monitoring study showed near perfect beat-to-beat accuracy (sensitivity = 99.1%, precision = 100%) on healthy subjects. In contrast, beat-to-beat detection from coronary artery disease patients was challenging, but the averaged heartrate was extracted successfully (95% CI: −1.2 to 1.1 bpm). In conclusion, the results indicate that the device could be useful in remote monitoring of cardiovascular diseases and personalized medicine.

health care sciences & services,medical informatics
Wearable Devices, Health Care Use, and Psychological Well-Being in Patients With Atrial Fibrillation

Lindsey Rosman,Rachel Lampert,Songcheng Zhuo,Quefeng Li,Niraj Varma,Matthew Burg,Allison E Gaffey,Tiffany Armbruster,Anil Gehi

DOI: https://doi.org/10.1161/JAHA.123.033750

2024-08-06

Abstract:Background: Wearables are increasingly used by patients with atrial fibrillation (AF) for symptom monitoring and health management, but their impact on patient health care use and psychological well-being is not well understood. Methods and results: In this retrospective, propensity-matched study of patients with AF, survey and electronic health record data were merged to compare AF-specific health care use (outpatient/inpatient visits, rhythm-related testing, and procedures) and informal health care use (telephone calls and patient portal messages) over a 9-month period between wearable users and nonusers. We also examined the effects of wearable cardiac monitoring features (eg, heart rate alerts, irregular rhythm notification, and ECG) on patient behavior and well-being. Of 172 patients with AF in this analysis (age, 72.6±9.0 years; 42% women), 83 used a wearable. Compared with nonusers, wearable users reported higher rates of symptom monitoring and preoccupation (P=0.03) and more AF treatment concerns (P=0.02). Moreover, 20% of wearable users experienced anxiety and always contacted their doctors in response to irregular rhythm notifications. After matching, AF-specific health care use was significantly greater among wearable users compared with nonusers (P=0.04), including significantly higher rates of ECGs, echocardiograms/transesophageal echocardiogram, and ablation. Wearable users were also significantly more likely to use informal health care resources compared with nonusers (P=0.05). Conclusions: Wearables were associated with higher rates of symptom monitoring and preoccupation, AF treatment concerns, AF-specific health care use, and use of informal health care resources. Prospective, randomized studies are needed to understand the net effects of wearables and their alerts on patients, providers, and the health care system.
Enhancing cardiac postoperative care: a smartwatch-integrated remote telemonitoring platform for health screening with ECG analysis

Rosangela Monteiro,Guilherme C M Rabello,Camila R Moreno,Matheus S Moitinho,Fábio A Pires,Nelson Samesina,Luiz Antônio M César,Flávio Tarasoutchi,Fábio Fernandes,Pietro C C O Martins,Bruna M Mariano,Alexandre de M Soeiro,Adriana Palhares,Carlos Alberto Pastore,Fabio B Jatene

DOI: https://doi.org/10.3389/fcvm.2024.1443998

2024-09-23

Abstract:Aims: The integration of smartwatches into postoperative cardiac care transforms patient monitoring, systematically tracking vital signs and delivering real-time data to a centralized platform. This study focuses on developing a platform for seamless integration, assessing reliability, and evaluating the impact on post-cardiac surgery. The goal is to establish a robust foundation for understanding the efficacy and dependability of smartwatch-based telemonitoring, enhancing care for this population. Methods and results: A total of 108 cardiac surgery patients were divided into telemonitoring (TLM) and control (CTL) groups. The TLM group utilized smartwatches for continuous monitoring of vital parameters (SpO2, HR, BP, ECG) over 30 ± 3 days. Statistical analyses (Pearson, Intraclass Correlation, Bland-Altman, Tost Test) were employed to compare smartwatch measurements with traditional methods. Significant correlations and concordance were observed, particularly in HR and BP measurements. Challenges were noted in SpO2 measurement. The ECG algorithm exhibited substantial agreement with cardiologists (Kappa: 0.794; p > 0.001), highlighting its reliability. The telemonitoring platform played a crucial role in early detection of clinical changes, including prompt Emergency Department (ED) visits, contributing significantly to preventing outcomes that could lead to mortality, such as asymptomatic Atrioventricular block. Positive patient responses affirmed technological efficacy, especially in identifying cardiac arrhythmias like atrial fibrillation. Conclusion: The integration of smartwatches into remote telemonitoring for postoperative cardiac care demonstrates substantial potential, improving monitoring and early complication detection, thereby enhancing patient outcomes. The FAPO-X Study (Assisted Digital Telemonitoring with Wearables in Patients After Cardiovascular Surgery; NCT05966857) underscores the promising role of telemonitoring in postoperative cardiac care.

Wearable smartwatch monitoring arrhythmias for patients who at high risk of pacemaker implantation after transcatheter aortic valve replacement

Wearable Smartwatch Facilitated Remote Health Management for Patients Undergoing Transcatheter Aortic Valve Replacement

Smartwatch Facilitated Remote Health Care for Patients Undergoing Transcatheter Aortic Valve Replacement Amid COVID-19 Pandemic

Smartwatch-Detected Arrhythmias in Patients After Transcatheter Aortic Valve Replacement (TAVR): Analysis of the SMART TAVR Trial

Ambulatory Smartwatch ECG Monitoring among Patients Undergoing Transcatheter Aortic Valve Replacement Early after Discharge: an Observational Study

Abstract 12465: Clinical Results of a Novel Chest-Based Wearable During Transcatheter Aortic Valve Replacement Surgery for Real-Time Remote Monitoring

Daily Physical Activity Measured by Wearable Smartwatch for Patients Undergoing Transcatheter Aortic Valve Replacement: Insights from the SMART TAVR Study.

Watch for tachycardia

The value of smart watch in diagnosis of atrial fibrillation and left bundle branch block after transcatheter aortic valve replacement

Myocardial Infarction Detected by a Smartwatch after Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic

Smart Wearables for Cardiac Monitoring-Real-World Use beyond Atrial Fibrillation

Remote monitoring of atrial fibrillation recurrence using mHealth technology (REMOTE-AF)

Smartwatch Performance for the Detection and Quantification of Atrial Fibrillation

Validation of diagnostic wearable ECG data from high-risk patients and integration into the atrial fibrillation catheter ablation pathway

The Use of Electrocardiogram Smartwatches in Patients with Cardiac Implantable Electrical Devices

Smart watch applications in atrial fibrillation detection: Current state and future directions

Cardiac Health Assessment Using a Wearable Device Before and After Transcatheter Aortic Valve Implantation: Prospective Study

Clinical assessment of a non-invasive wearable MEMS pressure sensor array for monitoring of arterial pulse waveform, heart rate and detection of atrial fibrillation

Wearable Devices, Health Care Use, and Psychological Well-Being in Patients With Atrial Fibrillation

Enhancing cardiac postoperative care: a smartwatch-integrated remote telemonitoring platform for health screening with ECG analysis